OzemPIC deficiency has ended
US food And drug administration It has been identified This toxelotide is no longer in a deficiency, a step that will have effects on patients who take cheaper and vehicle versions.
Semaglutide, the active ingredient in the beating diabetes in Novo Nordisk and weight loss drugs and Wujovi, has been included in the Food and Drug Administration List since March 2022. Novo Nordesk turned one of the most valuable companies in the world, with Market value More than the rest of the nation’s economy in Denmark.
In the decisive years, a profitable industry has arisen for remote health care companies, medical resorts, and pharmacies made and selling “vehicle” copies of medications. These copies are sold out of the brand with a sharp discount-sometimes less than $ 100 per bottle-the brand medications, which can exceed $ 1,000 per month without insurance.
At the end of October, the Food and Drug Administration (FDA) changed the condition of all OzemPic and Wegov doses to “available”, indicating that the end of the official shortage is likely to be on the horizon. It took it to this day, about four months later, until the organizers conclude that the drug was widely available enough to remove it from the deficiency list.
Food and Drug Administration It gives “503A” complexes, usually licensed pharmacies from the state or doctors ’complexes that manage smaller operations, until April 22 to stop producing the drug. It gives 503B complexes, and they are facilities to use larger external sources that track tougher manufacturing guidelines, until May 22.
Under normal circumstances, it is not particularly controversial when drugs are launched in the deficiency list. But there is a reason for the belief that players in this industry will return to this announcement.
Drug double is a solid practice. Pharmacists are allowed to create copies of medications when there is a lack of drugs or when patients need versions made in specific doses or without allergies. But the GLP-1 mutation has created an opportunity for vehicles that transformed the pockets of industry, as compound pharmacies produce repetitions outside the brand of potential millions of patients.
Robert McA Arter, director of pharmacy at the University of Rockefeller Hospital, says that once a medicine comes out of the FDA deficiency list, pharmacies use external sources that make large batches of compound medicines for healthcare facilities no longer supposed to outperform this medicine. But for smaller pharmacies and traditional vehicles that make medicines for home use, they are a legal gray area.
“They can assemble it if the doctor writes a prescription for an individual patient and feels that there is a convincing reason for the patient’s needs in this special compound product,” says Mac Arthur. This reason can be to adjust the dose or allocate the drug to a specific patient.
Some healthcare clothes indicated a distance from its intention to continue to provide their products. “Now that the Food and Drug Administration has determined that the lack of drugs in the vocations has been resolved, we will continue, founder, and executive head of his pride and health, books On X, adding that the company is closely monitoring the possible shortage in the future.